LONGEVERON INC-A (LGVN) Stock Price & Overview
NASDAQ:LGVN • US54303L2034
Current stock price
The current stock price of LGVN is 1.12 USD. Today LGVN is down by 0%. In the past month the price increased by 16.67%. In the past year, price decreased by -23.29%.
LGVN Key Statistics
- Market Cap
- 32.794M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.29
- Dividend Yield
- N/A
LGVN Stock Performance
LGVN Stock Chart
LGVN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LGVN. When comparing the yearly performance of all stocks, LGVN is one of the better performing stocks in the market, outperforming 86.43% of all stocks.
LGVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LGVN. The financial health of LGVN is average, but there are quite some concerns on its profitability.
LGVN Earnings
On March 17, 2026 LGVN reported an EPS of -0.23 and a revenue of 365.00K. The company beat EPS expectations (45.67% surprise) and beat revenue expectations (141.79% surprise).
LGVN Forecast & Estimates
8 analysts have analysed LGVN and the average price target is 6.74 USD. This implies a price increase of 502.21% is expected in the next year compared to the current price of 1.12.
For the next year, analysts expect an EPS growth of 51.37% and a revenue growth -24.99% for LGVN
LGVN Groups
Sector & Classification
LGVN Financial Highlights
Over the last trailing twelve months LGVN reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 69.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.26% | ||
| ROE | -400.07% | ||
| Debt/Equity | 0 |
LGVN Ownership
LGVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 371.899B | ||
| AMGN | AMGEN INC | 15.25 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.68 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.84 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.2 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.55 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LGVN
Company Profile
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Company Info
IPO: 2021-02-12
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136 US
CEO: Geoff Green
Employees: 38
Phone: 13053027158
LONGEVERON INC-A / LGVN FAQ
What does LONGEVERON INC-A do?
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
What is the stock price of LONGEVERON INC-A today?
The current stock price of LGVN is 1.12 USD.
What is the dividend status of LONGEVERON INC-A?
LGVN does not pay a dividend.
What is the ChartMill technical and fundamental rating of LGVN stock?
LGVN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is LONGEVERON INC-A (LGVN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LGVN.
How many employees does LONGEVERON INC-A have?
LONGEVERON INC-A (LGVN) currently has 38 employees.